Raymond James Financial
PLRX icon

Raymond James Financial’s Pliant Therapeutics PLRX Stock Holding History

Raymond James Financial’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-12
Closed -$14 – 6271
2025
Q2 		$14 Buy
+12
New +$17 ﹤0.01% 6937

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Raymond James Financial's PLRX Position: Q3 2025 in Review

Raymond James Financial sold out of Pliant Therapeutics (PLRX) in Q3 2025, closing a stake of 12 shares — an estimated $14 sold.

Raymond James Financial first reported a position in PLRX in Q2 2025 and held it in 1 quarter. The position peaked at $14 in Q2 2025. 99 funds tracked by Wall St. Rank hold PLRX as of Q3 2025.

  • Raymond James Financial reported no remaining Pliant Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 12 Pliant Therapeutics shares in Q3 2025, an estimated $14.
  • Raymond James Financial first reported a position in Pliant Therapeutics in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Pliant Therapeutics position peaked at $14 in Q2 2025.
  • 99 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.